 of those patients most likely to benefit from its
use, considering potential long-term disability, anatomic
distribution of thrombus, duration of symptoms, and the
risk of complications. Unfortunately, proving the efficacy of
these approaches in preventing the late manifestations of
the postthrombotic syndrome is substantially more difficult
than proving the efficacy of anticoagulants in preventing
recurrent VTE. Such trials require much longer periods of
follow-up and validated clinical and quality-of-life